181 related articles for article (PubMed ID: 36810288)
1. MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation.
Wang Y; Jia Z; Liang C; He Y; Cong M; Wu Q; Tian P; He D; Miao X; Sun B; Yin Y; Peng C; Yao F; Fu D; Liang Y; Zhang P; Xiong H; Hu G
Cell Discov; 2023 Feb; 9(1):20. PubMed ID: 36810288
[TBL] [Abstract][Full Text] [Related]
2. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
[TBL] [Abstract][Full Text] [Related]
3. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
4. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.
Liu X; Yin M; Dong J; Mao G; Min W; Kuang Z; Yang P; Liu L; Zhang N; Deng H
Acta Pharm Sin B; 2021 Oct; 11(10):3134-3149. PubMed ID: 34745852
[TBL] [Abstract][Full Text] [Related]
5. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
6. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
7. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
8. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
9. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression.
Hu Y; Lu Y; Xing F; Hsu W
Cancer Lett; 2022 Oct; 547():215867. PubMed ID: 35985510
[TBL] [Abstract][Full Text] [Related]
12. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.
Wang H; Yao H; Li C; Shi H; Lan J; Li Z; Zhang Y; Liang L; Fang JY; Xu J
Nat Chem Biol; 2019 Jan; 15(1):42-50. PubMed ID: 30397328
[TBL] [Abstract][Full Text] [Related]
13. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Tang H; Liu Y; Wang C; Zheng H; Chen Y; Liu W; Chen X; Zhang J; Chen H; Yang Y; Yang J
J Pharmacol Exp Ther; 2019 Mar; 368(3):401-413. PubMed ID: 30591531
[TBL] [Abstract][Full Text] [Related]
15. A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors.
Li J; Yan Y; Zhang P; Ding J; Huang Y; Jin Y; Li L
J Control Release; 2022 Nov; 351():231-244. PubMed ID: 36122899
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
17. Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.
Tong Q; Xu J; Wu A; Zhang C; Yang A; Zhang S; Lin H; Lu W
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432703
[TBL] [Abstract][Full Text] [Related]
18. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of
Baraibar I; Roman M; Rodríguez-Remírez M; López I; Vilalta A; Guruceaga E; Ecay M; Collantes M; Lozano T; Alignani D; Puyalto A; Oliver A; Ortiz-Espinosa S; Moreno H; Torregrosa M; Rolfo C; Caglevic C; García-Ros D; Villalba-Esparza M; De Andrea C; Vicent S; Pío R; Lasarte JJ; Calvo A; Ajona D; Gil-Bazo I
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33126649
[TBL] [Abstract][Full Text] [Related]
19. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity.
Yang S; Shim MK; Song S; Cho H; Choi J; Jeon SI; Kim WJ; Um W; Park JH; Yoon HY; Kim K
Biomaterials; 2022 Nov; 290():121841. PubMed ID: 36206664
[TBL] [Abstract][Full Text] [Related]
20. MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination.
Cong M; Wang Y; Yang Y; Lian C; Zhuang X; Li X; Zhang P; Liu Y; Tang J; Yang Q; Zhang X; Xiong H; Hu R; Hu G
Nat Cancer; 2020 Feb; 1(2):222-234. PubMed ID: 35122005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]